News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Nirmal Raut: BEST OF 2024 – Top oncology practice changing trials
jupiterhospital.com
Jan 2, 2025, 15:49

Nirmal Raut: BEST OF 2024 – Top oncology practice changing trials

Nirmal Raut, Consultant Medical Oncologist at Jupiter Hospital, shared a post on X:

“BEST OF 2024 – Top oncology practice changing trials –

1) EV-302 : EV + Pembrolizumab in first line adv/met urothelial Cancer

mOS – 31.5 m Vs 16.1 m for chemo;
mPFS – 12.5 m Vs 6.3 m for chemo;
ORR- 66.6 % Vs 44.4 %

Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer

Authors: Thomas Powles et al

Nirmal Raut

2) PEACE-3 Trial- Silke Gillesen – Ra 223 + enzalutamide improves PFS and OS than enzalutamide in mCRPC (PEACE -3)

LBA1 A randomized multicenter open label phase III trial comparing enzalutamide vs a combination of Radium-223 (Ra223) and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer (mCRPC): First results of EORTC-GUCG 1333/PEACE-3

Authors: Silke Gillesen et al.

Nirmal Raut: BEST OF 2024 - Top oncology practice changing trials

3) KEYNOTE A 18 -Domenica Lorusso shows that adding pembrolizumab to CT+RT in ca cx gives statistically OS benefit Vs CT+ RT”

Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial

Authors: Domenica Lorusso et al.

Nirmal Raut: BEST OF 2024 - Top oncology practice changing trials

Alejandro Acevedo Alexandra Drakaki Ana Oaknin Andrea Juliana Pereira de Santana Gomes Aude Fléchon Begoña P Valderrama Blanca Homet Moreno cancer Chih-Long Chang Christof Vulsteke Daniel Castellano Edgar Petru Eiji Kikuchi Ekkasit Tharavichitkul Fernando Contreras Mejía Flora Zagouri Giovanni Scambia Giuseppe Fornarini Gopa Iyer Hong Zhu Hüseyin Akıllı Ignacio Duran Jakub Cvek Jalid Sehouli Jean Hoffman-Censits Jens Bedke Jian-Ri Li Jung-Yun Lee Karin Yamada Kosei Hasegawa Kristina Lindemann Leslie Randall Limor Helpman Linda R Duska Lucy Gilbert Mahmut Gümüş Manuel Leiva Marketa Bednarikova Melissa Christiaens Michiel S. Van der Heijden Nataliya Mar Nicoletta Colombo OncoDaily Oncology Peng Liu Pier Ramos-Elias Sandro Pignata Sang Joon Shin Sarper Toker Se Hoon Park Seema Gorla Shilpa Gupta Silke Gillesen Stephen M Keefe Sujata Narayanan Thomas Powles Tomoka Usami Valeriya Saevets Xuesong Yu Yang Xiang Yohann Loriot
Special Coverage
Insight
Jan 5, 2025, 18:37
Roupen Odabashian: How to Study with AI
Insight
Jan 5, 2025, 18:34
Nazik Hammad: Faculty Development among African Oncologists
Blog
Jan 5, 2025, 18:32
David Agus: Shocking that there is a lack of trust in science
Insight
Jan 5, 2025, 18:26
Rahul Gosain: GISeries with Shubham Pant
Insight
Jan 5, 2025, 18:24
Monika Pansari: Introducing Aarambh
Insight
Jan 5, 2025, 18:21
Elisa Agostinetto: Drug-drug interactions between palbociclib and PPI in breast cancer
Blog
Jan 5, 2025, 18:13
Min-Han Tan: Cancer patients deserve the most informed treatment options
Blog
Jan 5, 2025, 18:11
Rolling into 2025 with hope, purpose and determination - City of Hope
Blog
Jan 5, 2025, 17:52
Zoë Mullan: Happy New Year from the Lancet Global Health team
Blog
Jan 5, 2025, 17:49
Amit Kumar Jain: The intricate and compelling journey of cancer
Blog
Jan 5, 2025, 17:46
A powerful moment during the annual POHER medical research and mentorship symposium
Career
Jan 5, 2025, 17:42
Alexandra Bailey's journey to Dana-Farber Cancer Institute